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ciation for Thoracic Surgerydoi:10.1016/j.jtcvs.2004.07.042Background: Atrial tachyarrhythmia is the most common complication after general
thoracic surgery and is associated with significant morbidity, longer hospital stay, and
higher costs. We sought to determine whether the use of antiarrhythmic medications is
associated with a reduced rate of postoperative atrial tachyarrhythmia.
Methods: MEDLINE, EMBASE, Cochrane Database of clinical trials (1980-2003), and
reference lists of relevant articles were searched for randomized controlled trials with
placebo control, general thoracic patients, and noncombined and prophylactic use of the
medications. Search, data abstraction, and analyses were performed and confirmed by at
least 2 authors. A fixed-effects model was used to perform meta-analyses.
Results: There were 11 unique trials (total n  1294) that met the inclusion criteria.
Calcium-channel blockers and -blockers reduced the risk of atrial tachyarrhythmia
in 4 and 2 trials, respectively (relative risk of 0.50 and 95% confidence interval of
0.34-0.73; relative risk of 0.40 and 95% confidence interval of 0.17-0.95, respec-
tively). However, -blockers tended to increase the risk of pulmonary edema
(relative risk, 2.15; 95% confidence interval, 0.74-6.23). Magnesium tested in one
unblinded trial also reduced the risk of atrial tachyarrhythmia (relative risk, 0.4;
95% confidence interval, 0.21-0.78). On the other hand, digitalis preparations were
found to be harmful because they increased the risk of atrial tachyarrhythmia in 3
trials (relative risk, 1.51; 95% confidence interval, 1.00-2.28). Finally, 2 other
medications, flecainide and amiodarone, were each tested in a single small trial, and
their effects were associated with great uncertainty.
Conclusions: Calcium-channel blockers and -blockers are effective in reducing
postoperative atrial tachyarrhythmia. The use of these medications should be indi-
vidualized, and possible adverse events of -blockers should be taken into account.
Randomized clinical trials do not support the use of digitalis in general thoracic
surgery. The value of magnesium as a supplement to a main prophylactic regimen
should be explored.
More than 78,000 lobectomies and pneumonectomies are performed annu-ally in the United States, and more than 5000 major noncardiac generalthoracic surgical procedures are being performed annually in the United
Kingdom.1,2 Atrial tachyarrhythmia (AT), predominantly atrial fibrillation, is the
most common complication after general thoracic surgery (GTS) and is associated
with stroke, longer hospital stay, and higher health care costs.3-6 Moreover, AT
seems to be a strong predictor of early7 and long-term5 mortality after general
thoracic surgical procedures for lung cancer. The reported incidence of AT ranges
from 13% to 46%,5,6,8 which is comparable with or even higher than the incidence
after coronary artery bypass grafting. Proposed causative mechanisms of AT after
GTS include increased pulmonary vascular resistance and systolic right ventricular
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TSpressure that might lead to a pressure-volume effect.9,10 In
addition, extensive surgical stress3 and increased sympa-
thetic activity,11,12 hypoxemia, and perioperative fluid over-
load12 were reported as other possible mechanisms. Major
risk factors for postoperative AT include previous treatment
(irradiation) and older age.3,10
Only a handful of studies were conducted to determine
whether antiarrhythmic medications could reduce the inci-
dence of AT in GTS. Although one recent review addressed
the usefulness of -blockers in noncardiac thoracic sur-
gery13,14 and the results of the study were suggested to be
applicable to GTS patients, the study mostly included trials
enrolling patients undergoing vascular surgery.
It would be inappropriate to apply the evidence found in
vascular surgical studies in the setting of GTS without
systematically reviewing the evidence of the effectiveness
of -blockers, as well as other pharmacologic interventions.
Most patients in GTS practice undergo resections for lung
cancer and have a long history of smoking and advanced
chronic obstructive pulmonary disease (COPD). Thus the
safety of the -blockers should also be determined because
pulmonary morbidity aggravated by large resections of the
lung (pneumonectomies and lobectomies) might interact
with operative stress and is likely to worsen pulmonary
dysfunction that might potentially be associated with
-blockers.15,16 Similarly, the safety profiles of other med-
ications that are used for arrhythmia prophylaxis are un-
known in GTS.
Therefore we sought to determine whether the use of
-blockers and other antiarrhythmic medications before or
during surgical intervention is associated with a reduced
rate of postoperative AT in GTS by systematically review-
ing available evidence from randomized clinical trials
(RCTs). We also sought to determine whether the use of
TABLE 1. Features of anti-arrhythmic medication trials inc
Trial
Prophylactic
medication
N
patie
Kaiser et al, 199426 Digitalis 6
Ritchie et al, 199329 Digitalis 8
Ritchie et al, 199317 Digitalis 5
Ritchie et al, 1990,28 199218 Digitalis 14
Amar et al, 20004 Diltiazem 33
Lindgren et al, 199127 Verapamil 2
Van Mieghem et al, 199431 Verapamil,
amiodarone
9
Van Mieghem et al, 199632 Verapamil 19
Bayliff et al, 199924 Propranolol 9
Jakobsen et al, 199711 Metoprolol 3
Borgeat et al, 198925 Flecainide 3
Terzi et al, 199630 Magnesium 20antiarrhythmic medications is associated with hypotension,
998 The Journal of Thoracic and Cardiovascular Surgery ● Maybradycardia, severe pulmonary complications, myocardial
ischemia, or mortality.
Methods
Types of Studies and Participants
Only RCTs comparing antiarrhythmic medications with placebo
control were included. The following inclusion criteria were ap-
plied: (1) random allocation of study treatments, (2) placebo con-
trol, (3) enrollment of only patients undergoing GTS, (4) no use of
another experimental medication or device, and (5) prophylactic
use of the antiarrhythmic medication. Patients undergoing heart-
lung transplantation or pediatric operations were excluded.
For each trial, reported data on arrhythmia, bradycardia, hypo-
tension, severe pulmonary complication, myocardial ischemia, and
mortality were collected in the intervention and control groups.
Search Strategy for Identification of Studies
RCTs were identified by searching MEDLINE, EMBASE, and the
Cochrane Controlled Trials Register from 1980 through 2003.
Only studies in human subjects were considered, and no language
restriction was applied. In addition, we searched the reference lists
of RCTs and reviews to look for additional studies.
A standard RCT filter designed by the Cochrane Collaboration
for identifying RCTs was used for MEDLINE and EMBASE.
These search algorithms are available at the Scottish Intercolle-
giate Guideline Network Web site (http://www.sign.ac.uk/method
ology/filters.html). The strategy (with MeSH and text terms) used
to search the databases is outlined in Appendix 1.
Search of the above databases identified 262 unique abstracts.
These were independently reviewed for relevance for review,
which was independently performed by 2 authors (A.S. and
J.V.M.). Independent review of these abstracts identified 16 unique
studies after excluding multiple publications from the same tri-
als.17-19 On detailed review, 5 of the 16 studies did not meet the
predefined inclusion criteria. One of the rejected studies random-
ized patients undergoing heart-lung transplantation,20 2 studies
d in the systematic review
Mean age
(y)
%
female
%
pneumonectomy
n/a n/a 26
64 n/a 0
62 n/a 0
60 n/a 14
66 46 19
62 0 20
n/a n/a 33
60 n/a 35
62 38 22
60 33 33
55 n/a 7
64 n/a 20lude
of
nts
5 
0 
0 
0 
0 
5 
6
9 
9 
0 
0 were found to be nonrandomized trials,8,21 1 study enrolled cardiac
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TSsurgical patients,22 and 1 study related to short-acting -blocker
(esmolol) use during anesthesia to measure responses to laryngos-
copy and did not report information on any of the outcomes of
interest.23 The remaining 11 unique studies4,11,17,24-32 met the
inclusion criteria.
For each trial, abstracted data included the frequency of the
events in the medication and placebo groups, as well as the
numbers of patients randomized to the treatment groups. Other
abstracted data included mean age, sex, publication date, blinded
allocation of the study drug, and number of dropouts. One of the
authors (A.S.) abstracted the data, and another coauthor (J.B.)
independently confirmed the counts of events and the number of
patients randomized to treatment groups. All authors participated
in adjudication of any discrepancies. Corresponding authors of all
selected studies were contacted to learn about missing information.
Reports-descriptions such as “no major complications were ob-
served in the study” were not considered as zero events. Only
explicit description of outcome events was accepted as a valid
count. If the primary investigator did not reply to personal com-
munication within a 4-week period and if the article did not
contain information on the adverse event of interest, then the end
Figure 1. Forest plot of RRs (95% CIs) of ATpoint was left as a missing value.
The Journal of ThoraciAT was evaluated on the basis of reports of “supra-ventricular
tachycardia,” “atrial fibrillation,” “atrial flutter,” and “atrial tachy-
arrhythmia.” Hypotension and bradycardia incidences were based
on the reported incidences of these conditions. The criteria for
severe pulmonary complications were reports of “pulmonary
edema” and “adult respiratory distress syndrome (ARDS).” Myo-
cardial ischemia measurement was based on the reports of “myo-
cardial ischemia” or “myocardial infarction.” Mortality mostly
included in-hospital clinical diagnosis of death. The methods of
ascertainment of the events differed in the trials. However, within
each trial, they were applied equally to the 2 treatment groups.
Statistical Analyses
The risk estimates for AT, hypotension, bradycardia, severe pul-
monary complication, and myocardial ischemia in the medication
and placebo groups were assessed separately for each medication.
Information from the trials was combined by using the inverse
variance-based method, which incorporates a fixed-effects model
and assumes that studies under examination share a common true
effect size, that the sampling distribution of these effects is normal,
ified by class of antiarrhythmic medication.stratand that all the variability is due to sampling error (homogeneity
c and Cardiovascular Surgery ● Volume 129, Number 5 999
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TSassumption). In this model the weights of individual studies cor-
respond to the inverse of the total variance for each study. Because
the assumption of homogeneity was not rejected when testing with
the 2 statistic, we did not use a random-effects model. The
standard error of the pooled risk ratio (RR) estimate was used to
calculate 95% confidence intervals (CIs). Numbers needed to treat
and their CIs were also calculated by risk difference (RD) analysis.
RD statistics were particularly important in the trials with 0 events,
in which RR was not estimable. In these instances RD statistics
still provided estimates of uncertainty around 0. On the basis of
number-needed-to-treat statistics, the numbers of events averted-
induced were calculated per 100 procedures.
Because each class of medication was considered qualitatively
different from another, only subgroup analyses were performed for
each class of medication, and no single estimate for all medications
was calculated. RevMan 4.2, developed by the Cochrane Collab-
oration, was used in all analyses.
The methodologic quality of the included studies was evaluated
by using the Jadad criteria,33 which are based on the following: (1)
TABLE 2. Atrial tachyarrhythmia, hypotension, and bradyc
Trial
Atrial tach
events/#
Medication
Calcium channel blockers
Amar et al, 20004 25/167
Lindgren et al, 199127 0/12
Van Mieghem et al, 199431 0/32
Van Mieghem et al, 199632 8/100
RR and events per 100 exposed patients (95% CI) 0.50 (0
11 (
Beta-blockers
Bayliff et al, 199924 3/49
Jakobsen et al, 199711 3/15
RR and events per 100 exposed patients (95% CI) 0.40 (0
14 (
Magnesium
Terzi et al, 199630 10/93
RR and events per 100 exposed patients (95% CI) 0.40 (0
16 (
Digitalis
Kaiser et al, 199426 10/30
Ritchie et al, 199317,29 12/39
Ritchie et al, 1990,28 199218 20/70
RR and events per 100 exposed patients (95% CI) 1.51 (1
10 (0
Flecainide
Borgeat et al, 198925 0/14
RR and events per 100 exposed patients (95% CI) 0.16 (0
19 (
Amiodarone
Van Mieghem et al, 199431 1/32
RR and events per 100 exposed patients (95% CI) 0.14 (0
19 (
RR, Relative risk; CI, confidence intervals; n/a, not available“randomized” study description, (2) description of correct random-
1000 The Journal of Thoracic and Cardiovascular Surgery ● Maization procedure, (3) double-blinding study description, (4) de-
scription of correct double blinding, and (5) dropouts and adequate
description of the end points of interest.
The overall quality score was based on the number of criteria
met (score range, 1-5).
Results
There were 1294 patients in the 11 trials of antiarrhythmic
medications. The average age was reported in 9 trials and
was 63.2 years (Table 1). Patient sex was reported in only 4
trials, and 41.3% of the patients in these trials were female.
Pneumonectomy was performed in 20.9% of patients. There
were 3 trials investigating the efficacy and safety of digi-
talis,26,28,29 4 more trials on calcium-channel blockers (3
studies of verapamil and 1 study of diltiazem),4,27,31,32 2
trials of -blockers (1 trial of metoprolol and 1 of propran-
olol),11,24 and single trials of amiodarone,31 flecainide,25
in the Trials
ythmia
mized
Hypotension events/#
randomized
Bradycardia events/#
randomized
Placebo Medication Placebo Medication Placebo
40/163 6/167 1/163 n/a n/a
4/13 0/12 0/13 0/12 0/13
7/32 3/32 1/32 0/32 0/32
15/99 14/100 0/99 9/100 0/99
.73) 9.29 (2.55-33.87) 18.81 (1.11-318.88)
5) 7 (4 to 10) 6 (2 to 11)
8/50 24/49 13/50 12/49 2/50
7/15 n/a n/a n/a n/a
.95) 1.88 (1.09-3.26) 6.12 (1.44-25.95)
2) 23 (4 to 42) 20 (7 to 34)
27/101 0/95 0/105 0/93 0/101
.78) RR not estimable Not estimable
5) 0 (2 to 2) 0 (2 to 2)
4/35 n/a n/a 6/30 0/35
9/41 n/a n/a n/a n/a
16/70 n/a n/a 4/70 2/70
.28) 4.46 (1.17-16.94)
0) 8 (2 to 15)
3/16 8/14 0/16 0/14 0/16
.89) 19.27 (1.21-306.35) Not estimable
o 3) 57 (31 to 83) 0 (12 to 12)
7/32 1/32 1/32 1/32 0/32
.10) 1.00 (0.07-15.30) 3.0 (0.13-71.00)
3) 0 (9 to 9) 3 (5 to 11)ardia
yarrh
rando
.34-0
17 to
.17-0
26 to
.21-0
27 to
.00-2
to 2
.01-2
40 t
.02-1
34 toand magnesium.30 One trial31 randomized patients into 3
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TSarms (calcium-channel blocker, amiodarone, and placebo),
and it was included in both the calcium-channel blocker and
amiodarone subgroup analyses. Overall quality scores
ranged from 2 to 5. Sensitivity analyses have shown that
methodologic grading had no effect on the estimate of the
effect for any of the outcomes of interest.
Atrial Tachyarrhythmia
Calcium-channel blockers. All 4 trials assessed AT and
enrolled 618 patients. The overall incidence was 10.6% in
the medication groups and 21.5% in the placebo groups
(RR, 0.50; 95% CI, 0.34-0.73). There was evidence of 11
episodes of AT averted per 100 patients treated (95% CI,
17 to 5; Figure 1 and Table 2).
-Blockers. There were 2 trials reporting AT that en-
rolled 129 patients. The overall incidence was 9.4% in the
medication groups and 23.1% in the placebo groups (RR,
TABLE 3. Severe pulmonary complications, myocardial isc
Trial
SPC events
Medication
Calcium channel blockers
Amar et al, 20004 4/167
Lindgren et al, 199127 0/12
Van Mieghem et al, 199431 0/32
Van Mieghem et al, 199612 4/100
RR and events per 100 exposed patients (95% CI) 1.31 (0
1 (
Beta-blockers
Bayliff et al, 199924 8/49
Jakobsen et al, 199711 1/15
RR and events per 100 exposed patients (95%CI) 2.15 (0
8 (
Magnesium
Terzi et al, 199630 n/a
RR and events per 100 exposed patients (95% CI)
Digitalis
Kaiser et al, 199426 n/a
Ritchie et al, 199317,29 n/a
Ritchie et al, 1990,28 199218 n/a
RR and events per 100 exposed patients (95% CI)
Flecainide
Borgeat et al, 198925 0/14
RR and events per 100 exposed patients (95% CI) Not e
Amiodarone
Van Mieghem et al, 199431 3/32
RR and events per 100 exposed patients (95%CI) 7.00 (0.
9 (
RR, Relative risk; CI, confidence intervals; SPC, severe pulmonary complic0.40; 95% CI, 0.17-0.95). There was evidence of 14 epi-
The Journal of Thoracicsodes of AT averted per 100 patients treated (95% CI, 26
to 2).
Magnesium. There was one trial enrolling 194 patients.
The overall incidence was 10.7% in the medication group
and 26.7% in the placebo group (RR, 0.40; 95% CI, 0.21-
0.78), and 16 episodes of AT were estimated to be averted
per 100 patients administered magnesium (95% CI, 27
to 5).
Digitalis. AT was assessed in all 3 trials of digitalis,
which included 285 patients (Figure 1 and Table 2). In 2 of
the trials the incidence of “dysrhythmia” was reported,28,29
whereas in the third trial the incidence of AT was deter-
mined. The overall incidence was 30.2% in the digitalis
groups and 19.9% in the placebo groups (RR, 1.51; 95% CI,
1.00-2.28).
Flecainide. There was one trial enrolling 30 patients.
The overall incidence was 0% in the medication group and
ia, and mortality in the Trials
domized Myocardial ischemia
Mortality events/#
randomized
Placebo Medication Placebo Medication Placebo
3/163 0/167 0/163 1/167 3/163
0/13 0/12 3/13 0/12 0/13
0/32 n/a n/a 3/32 1/32
3/99 n/a n/a 4/100 3/100
.72) 0.15 (0.01-2.70) 1.13 (0.42-3.06)
3) 2 (4 to 1) 0 (2 to 3)
4/50 1/50 3/49 2/49 1/50
0/15 1/15 0/15 n/a n/a
.23) 0.71 (0.14-3.46) 2.09 (0.18-23.77)
9) 2 (9 to 6) 2 (5 to 9)
n/a n/a n/a 1/93 1/101
1.09 (0.07-17.63)
0 (3 to 3)
n/a n/a n/a n/a n/a
n/a n/a n/a 3/39 2/41
n/a n/a n/a n/a n/a
1.63 (0.26-10.29)
3 (8 to 13)
0/16 0/14 0/16 0/14 0/16
ble Not estimable Not estimable
0/32 n/a n/a 2/32 0/32
0.26) 5.33 (0.25-115.50)
1) 6 (4 to 16)
s, n/a, not availablehem
/# ran
.46-3
2 to
.74-6
3 to 1
stima
38-13
2 to 218.7% in the placebo group (RR, 0.16; 95% CI, 0.01-2.89).
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The overall incidence was 3.1% in the medication group and
21.9% in the placebo group (RR, 0.14; 95% CI, 0.02-1.10).
Hypotension and Bradycardia
Calcium-channel blockers. Four trials (total n  618)
reported the incidence of hypotension, and 3 trials (total n
290) reported the incidence of bradycardia (Table 2). The
overall incidence of hypotension was 7.4% in the medica-
tion groups and 0.6% in the placebo groups (RR, 9.29; 7
additional events per 100 patients treated). Bradycardia
occurred in 6.2% of the medication groups and in 0% of the
placebo groups (RR, 18.81; 6 additional events per 100
patients treated).
-blockers. One trial24 (n  99) reported information
on -blockers (Table 2). The incidence of hypotension was
49.0% in the medication group and 26.0% in the placebo
group (RR, 1.88; 23 additional events per 100 patients
treated). The incidence of bradycardia was 24.5% in the
medication group and 4.0% in the placebo group (RR, 6.12;
20 additional events per 100 patients treated).
Magnesium. There were 0 events of hypotension and
bradycardia reported in the trial (n  194; RR not estimable
with 0 additional events).
Digitalis. No information on hypotension was available
in the studies. Bradycardia was assessed in 2 trials, which
included 209 patients (Table 2). The overall incidence was
9.8% in the digitalis groups and 1.9% in the placebo groups
(RR, 4.46; 8 additional incidences of bradycardia per 100
patients treated).
Flecainide. The overall incidence of hypotension was
57.1% in the medication group and 0% in the placebo group
(per investigator report; RR, 19.27; 57 additional events of
hypotension per 100 patients treated). There were no events
of bradycardia reported in 30 enrolled patients.
Amiodarone. The incidence of hypotension was 3.1% in
the medication group and 3.1% in the placebo group. Bra-
dycardia occurred in 3.1% of the medication group and 0%
of the placebo group (Table 2).
Severe Pulmonary Complications
Calcium-channel blockers. All 4 trials (total n  618)
reported the incidence of ARDS (Table 3). The overall
incidence was 2.6% in the medication groups and 2.0% in
the placebo groups (RR, 1.31; with a tendency of one
additional event per 100 patients treated; Table 3.
-blockers. Both trials (n  129) reported information
on pulmonary edema rather than ARDS. The overall inci-
dence was 14.1% in the medication groups and 6.2% in the
placebo groups (RR, 2.15; with a tendency toward 8 addi-
tional events per 100 patients treated).
Magnesium. There was no information on the incidence
of this outcome in the study.
1002 The Journal of Thoracic and Cardiovascular Surgery ● MaDigitalis. No information on the incidence of this out-
come was available in the studies.
Flecainide. There were 0 events reported in the trial
(n  194).
Amiodarone. The overall incidence reported was for
ARDS, and it occurred in 9.4% of the medication group and
0% of the placebo group (RR, 7.00; with a tendency toward
9 additional events per 100 patients treated).
Myocardial Ischemia and Mortality
There were few outcomes of interest reported in all trials.
Given the rare incidence of these outcomes, the safety of the
medications was more reliably estimable for calcium-
channel blockers because there were 359 patient-based re-
ports for myocardial ischemia and 618 patient-based reports
for mortality. The estimates for other medications were
associated with much greater uncertainty (Table 3).
Discussion
In this systematic review we report evidence from 11 pla-
cebo-controlled RCTs of antiarrhythmic medications that
were tested in a total of 1294 patients undergoing GTS.
Although calcium-channel blockers, -blockers, and mag-
nesium preparations were associated with a reduced risk of
AT, digitalis preparations were associated with a higher risk
of arrhythmia compared with placebo. Two other medica-
tions, flecainide and amiodarone, were each tested in single
small trials, and their effects were associated with great
uncertainty. The advantages of our study include relatively
large sample sizes and the ability to pool the effects from
small and underpowered individual studies. In addition, we
found that the average weighted age was 63.2 years, and
pneumonectomies were performed in 20.9% of patients,
which is in line with the current practice of GTS. Moreover,
the incidence of AT in the placebo groups was generally
similar across the trials and in a range of 16% to 26% in
most studies, which supports the validity of relative com-
parisons between the medications.
Calcium-channel blockers and -blockers were associ-
ated with a reduction in AT to less than half of the incidence
seen in the control patients. Our estimates were robust and
show 11 to 14 AT reductions per 100 patients administered
these medications. These medications were reported to be
associated with increased risk of hypotension and bradycar-
dia. The severity and definitions of these events were not
reported in the trials, but accepting definitions provided by
the authors, 7 cases of hypotension and 6 cases of brady-
cardia were associated with calcium-channel blockers, and
23 cases of hypotension and 20 cases of bradycardia were
associated with -blockers per 100 treated patients. The
higher incidence of these events in the -blocker group
might be related to fewer trials and different definitions
rather than qualitative differences between these 2 classes of
y 2005
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temporary events and disappeared after discontinuation of
the medication. Thus these findings should be interpreted as
a note of caution in the GTS population and should not
influence the policy of arrhythmia prophylaxis.
In our study -blockers tended to be associated with
pulmonary edema in one trial.24 Although personal commu-
nication with the investigators revealed no ARDS (a mea-
sure of the severe pulmonary dysfunction in calcium-chan-
nel blocker trials), the Cochrane review of -blocker use in
the population with COPD also reported a tendency toward
a higher risk of pulmonary dysfunction.15,16 Thus there is a
theoretic possibility that -blockers might interact with
operative stress in the GTS setting and worsen preexisting
pulmonary dysfunction in patients with lung cancer who
have long-term smoking histories and COPD.
Calcium-channel blockers, on the other hand, are known
to reduce pulmonary vascular resistance and right ventric-
ular pressure in addition to their antiarrhythmic effects.10,27
Thus they are less likely to cause pulmonary complications.
Moreover, their beneficial effect on pulmonary vascular
resistance might be valuable in lobectomies and pneumo-
nectomies, in which there is a concern of increased pulmo-
nary vascular resistance. Thus one might argue that for
larger resections, advanced COPD, and intolerance of
-blockers, calcium-channel blockers should be the first
choice. The costs of the calcium-channel blockers should be
considered, and generic brands should be preferred. The
evidence for calcium-channel blockers is limited to vera-
pamil and diltiazem intravenous formulations, and there
appears to be no difference between these medications.
The effectiveness of -blockers and calcium-channel
blockers in cardiac surgery was recently summarized. The
evidence of halved risk of atrial fibrillation associated with
-blockers found in the review by Crystal and associates34
in cardiac surgery and Auerbach and Goldman13 in noncar-
diac surgery (non-GTS) is being rapidly popularized. How-
ever, a similar review by Wijeysundera and colleagues35
that also found comparable benefits associated with calci-
um-channel blockers in cardiac surgery had not received as
much attention. Moreover, the latter study reported a more
than 40% reduction of postoperative myocardial infarction
and a more than 45% reduction of myocardial ischemia
associated with calcium-channel blockers, evidence that
was not found for -blockers.
Because -blockers were found to be very useful in
reducing mortality after myocardial infarction, there seems
to be a trend toward recommending this group of medica-
tions in most settings without extensive research on other
alternatives or specifics of patient populations. We believe
that GTS is the area in which calcium-channel blockers
should be considered of equal value if not a first choice.
The Journal of ThoracicMagnesium was tested in one large unblinded trial of 200
patients. It was shown to be associated with a 2.5 times
reduction in the risk of AT and 16 event reductions in 100
patients administered magnesium. One limitation of this
trial was digitalis use in some control patients. Furthermore,
RCTs conducted on patients undergoing heart surgery re-
port controversial findings. Although Wollert and cowork-
ers22 also reported reduced risk of AT in cardiac surgery, a
number of other investigators did not find any difference
between magnesium and placebo.36,37 On the other hand,
Wilkes and associates38 found a reduced risk of AT when
magnesium was supplemented after measuring levels of
ionized plasma magnesium. The value of magnesium as a
supplement to the main antiarrhythmia regimen warrants
further investigation.
Three RCTs of digitalis reported dysrhythmia inci-
dence,28,29 and we found a 51% higher risk of arrhythmia
for digitalis compared with that for placebo (RR, 1.51; 95%
CI, 1.00-2.28). Moreover, digitalis was associated with a
more than 4 times higher risk of bradycardia compared with
placebo. In 2 other RCTs comparing digoxin with dilti-
azem39 and flecainide,40 the former was shown to be infe-
rior. Digitalization is still being used quite often in GTS
according to one recent review.3 Thus this finding should
help clinicians to discontinue the use of this antiarrhythmic
medication in GTS.
Flecainide and amiodarone were each tested in only one
trial, and reduction of arrhythmic events in the intervention
groups was reported. Borgeat and coworkers25 have shown
overall reduction of arrhythmic events (6 in control and 0 in
placebo), but the study was too small (n  30) to address
our end point of AT (3 in control and 0 in placebo). Personal
communication with the investigator revealed a high inci-
dence of hypotension in the medication group. Although
van Mieghem and associates31 reported a significant reduc-
tion of AT for amiodarone (RR, 0.16) in a sample of 62
patients (unblinded study), they were urged to stop the trial
because of 3 cases of ARDS (2 deaths) observed in the
amiodarone arm. In another study conducted in patients
undergoing cardiac surgery, amiodarone was associated
with a longer duration of cardiovascular instability and a
longer need for intensive care.37 Thus we believe that there
is inconclusive evidence to support the use of these
medications.
Although we had some limitations, such as the inability
to fully explore the safety of medications regarding mortal-
ity and myocardial ischemia or to perform further subgroup
analyses (by type of procedure or medication), we believe
that these limitations are not substantial. Furthermore, these
findings have important implications in the current practice
of GTS. Given the high incidence of AT, the use of proper
antiarrhythmic prophylaxis can potentially prevent more
than 1000 events in the United Kingdom and more than
and Cardiovascular Surgery ● Volume 129, Number 5 1003
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TS7800 events in the Unites States (halving the baseline inci-
dence rate of approximately 20% in 10,000 and 78,000
procedures, respectively). Moreover, antiarrhythmic medi-
cations are generally inexpensive, and substantial costs sav-
ings can also be expected because AT is associated with up
to $10,000 in additional costs per incidence41 and an addi-
tional 2 to 5 days of hospital stay in the studies of coronary
artery bypass grafting surgery.41,42
Conclusions
Calcium-channel blockers and -blockers are effective in
reducing postoperative AT. The use of these medications
should be individualized, and possible adverse events asso-
ciated with -blockers should be taken into account. The
value of magnesium as a supplement to a main prophylactic
regimen should be explored. RCTs do not support the use of
digitalis in GTS.
We thank Dr David Amar, Dr Charles Bayliff, Dr Walter Van
Mieghem, Dr Leena Lindgren, Dr Alan Borgeat, and Dr Antonio
Terzi for providing additional information from the trials of anti-
arrhythmic medications.
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Appendix 1
Medline Search Strategy
{1 exp Anti-Arrhythmia Agents/ (152477); 2 ((antiarrhythm$ or
anti-arrhythm$ or arrhythm$) adj2 (drug$ or agent$ or ther-
ap$)).tw. (10205); 3 (tachycardia or antiarrhythm$ or anti-ar-
rhythm$ or arrhythm$).tw. (63738); 4 exp Arrhythmia/ (101335);
5 (tachycardia or antiarrhythm$ or anti-arrhythm$ or arrhyth-
m$).tw. (63738); 6 ((atrial or atrium or auricular) adj6 (flutter$ or
fibrillat$)).tw. (14810); 7 or/4-6 (126560); 8 exp drug therapy/
(249078); 9 (dt or pc or tu).fs. (1644964); 10 or/8-9 (1715378); 11
7 and 10 (37925); 12 or/1-2,11 (172231); 13 exp Thoracic Surgery/
(4215); 14 thoracic surgical procedures/ or exp pulmonary surgical
procedures/ or thoracoplasty/ or thoracostomy/ or thoracotomy/ or
thymectomy/ or tracheostomy/ or tracheotomy/ (47756); 15 ((tho-
racic or lung or pulmon$ or bronch$) adj6 (surgery or surgical or
The Journal of Thoracicresect$)).tw. (29046); 16 (lobectom$ or pneumonectom$ or seg-
mentectom$ or esophagotom$ or thoracotom$).mp. (26886); 17
or/13-16 (81182); 18 (Randomized controlled trials/ or Random-
ized controlled trial.pt. or Random allocation/ or Double blind
method/ or Single blind method/ or Clinical trial.pt. or exp clinical
trials/ or (clinic$ adj trial$1).tw. or ((singl$ or doubl$ or treb$ or
tripl$) adj (blind$3 or mask$3)).tw. or Placebos/ or Placebo$.tw.
or Randomly allocated.tw. or (allocated adj2 random).tw.) not
(Case report.tw. or (Letter or Historical article or Review of
reported cases or Review, multicase).pt.) (487507); 19 Animal/ not
(Animal/ and Human/) (2680505); 20 (12 and 17 and 18) not 19
(126); 21 from 20 keep 1-10 (10); 22 from 20 keep 1-126 (126)}.
EMBASE Search Strategy
{1 exp Anti-arrhythmic Agent/ (141109); 2 ((antiarrhythm$ or
anti-arrhythm$ or arrhythm$) adj2 (drug$ or agent$ or ther-
ap$)).tw. (9437); 3 exp Heart Arrhythmia/ (93508); 4 ((atrial or
atrium or auricular) adj6 (flutter$ or fibrillat$)).tw. (12554); 5
(tachycardia or antiarrhythm$ or anti-arrhythm$ or arrhythm$).tw.
(52599); 6 or/3-5 (109070); 7 exp drug therapy/ (550418); 8 dt.fs.
(884591); 9 pc.fs. (215522); 10 or/7-9 (1328322); 11 6 and 10
(44577); 12 or/1-2,11 (168518); 13 thorax surgery/ or exp lung
surgery/ (17802); 14 ((thoracic or lung or pulmon$ or bronch$)
adj6 (surgery or surgical or resect$)).tw. (19362); 15 (lobectom$
or pneumonectom$ or segmentectom$ or esophagotom$ or thora-
cotom$).mp. (16394); 16 or/13-15 (42459); 17 (Clinical trial/ or
Randomized controlled trial/ or Randomization/ or Single blind
procedure/ or Double blind procedure/ or Crossover procedure/ or
(Randomi?ed controlled trial$ or rct or random allocation or ran-
domly allocated or allocated randomly or (allocated adj2 random)
or single blind$ or double blind$ or ((treble or triple) adj blind$)
or placebo$).tw. or Prospective study/) not (Case study/ or Case
report.tw. or Abstract report/ or letter/) (348963); 18 Animal/ not
(Animal/ and Human/) (12687); 19 (12 and 16 and 17) not 18
(136); 20 from 19 keep 1-136 (136)}.
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